SCHEMBL6940657

SCHEMBL6940657

CO[C@@H]1[C@H](O)[C@@H](OC2CCCCO2)[C@H](Oc2ccc3c(O)c(C(C)=O)c(=O)oc3c2C)OC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
HSP90AB1 P08238 3/20 0.44
HSP90AA1 P07900 2/20 0.44
MAP1LC3B Q9GZQ8 2/20 0.44
MAP1LC3A Q9H492 2/20 0.44
POLQ O75417 1/20 0.44
ALB P02768 1/20 0.44
KDR P35968 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6941760 1.00 LMNA (0.44) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A
SCHEMBL6943894 0.94 HSP90AB1 (0.43) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A
SCHEMBL6943889 0.94 HSP90AB1 (0.43) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A
SCHEMBL7075739 0.93 LMNA (0.45) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A
SCHEMBL7074596 0.93 LMNA (0.45) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A
SCHEMBL6864422 0.91 HSP90AB1 (0.42) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A
SCHEMBL6864423 0.91 HSP90AB1 (0.42) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A
SCHEMBL6939405 0.91 LMNA (0.41) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A
SCHEMBL7075879 0.91 LMNA (0.41) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A
SCHEMBL6860198 0.90 LMNA (0.41) LMNAHSP90AB1HSP90AA1MAP1LC3BMAP1LC3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583119-B2 Aromatic antibiotics such as 7-((6-deoxy-5-methyl-4-methyl-hexopyranosyl)oxy)-4-hydroxy-8-methyl-3-(1 -(phenoxyimino) ethyl)-2H-1-benzopyran-2-one (2-propynyloxy)-carbamic 3'-ester acid, for prevention of grampositive bacterial infections AVENTIS PHARMA S.A. (FR) 2003-06-24 US disclosed
EP-1045856-B1 NOVEL AROMATIC AMIDES, PREPARATION METHOD AND APPLICATION AS MEDICINES AVENTIS PHARMA SA (FR) 2003-04-09 EP disclosed
US-20030060609-A1 Novel aromatic amides, preparation method and application as medicines AVENTIS PHARMA S.A. 2003-03-27 US disclosed
US-6420538-B1 COMPOUND FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS AVENTIS PHARMA S.A. (FR) 2002-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060609-A1 Novel aromatic amides, preparation method and application as medicines NRDC, NPR1, NR4A1 LMNA 882/4885HSP90AB1 1953/4885HSP90AA1 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.